Completed PHASE4 INTERVENTIONAL 2-arm NCT00172809

Interferon Treatment for Patients With Chronic Hepatitis C and End Stage Renal Disease

A Pilot Study in Comparing the Efficacy and Safety of Peginterferon Alfa-2a and Interferon Alfa-2a in Treating Patients With End Stage Renal Disease and Chronic Hepatitis C

Sponsor: National Taiwan University Hospital

Conditions Chronic Hepatitis C End Stage Renal Disease

Interventions Interferon alfa-2a Peginterferon alfa-2a

Updated 6 times since 2017 Last updated: Mar 5, 2008 Started: Jul 31, 2005 Primary completion: Jun 30, 2006 Completion: Jan 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Chronic Hepatitis C and End Stage Renal Disease and is currently completed. National Taiwan University Hospital leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jul 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Taiwan University Hospital

Data source: National Taiwan University Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Douliu, Taiwan